|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
19 February 2015 |
|
Main ID: |
NCT01107067 |
|
Date of registration:
|
19/04/2010 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Testosterone Replacement Therapy Decreases Plasma Paraoxonase 1 Enzyme Activity In Male Patients With Hypogonadism
|
|
Scientific title:
|
Phase IV Study to Investigate the Effect of Testosterone Treatment on Paraoxonase Level in Male Patients With Hypogonadotrophic Hypogonadism |
|
Date of first enrolment:
|
June 2008 |
|
Target sample size:
|
32 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT01107067 |
|
Study type:
|
Interventional |
|
Study design:
|
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening
|
|
Phase:
|
Phase 4
|
|
|
Countries of recruitment
|
|
Turkey
| | | | | | | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Volunteers patients with hypogonadism
Exclusion Criteria:
- Coronary heart disease
- Other pituitary/hypothalamic disorders or other non-hypogonadism diseases
- None was receiving vitamins, lipid-lowering drugs, or other medications known to
interfere with PON1 activity, lipid profile, or gonadal function
Age minimum:
20 Years
Age maximum:
25 Years
Gender:
Male
|
|
Health Condition(s) or Problem(s) studied
|
|
Hypogonadism
|
|
Intervention(s)
|
|
Drug: Sustanon
|
|
Primary Outcome(s)
|
|
paraoxonase level after testosterone treatment
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|